Lancashire and South Cumbria
Formulary
Formulary
8 Malignant disease and immunosuppression
This chapter of the formulary has not been published, please use local guidelines.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
08-02-04 BCG bladder instillation
Links
Drug Safety Udate April 2016: Natalizumab (Tysabri): progressive multifocal leukoencephalopathy - updated advice to support early detection - LSC Breast Chemotherapy Protocols
- MHRA advice on risk of thromboembolism (Feb 2011)
- MHRA Drug Safety Update April 2016: Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy
- MHRA Drug Safety Update Dec 2017: Fingolimod (Gilenya): new contraindications in relation to cardiac risk
- MHRA Drug Safety Update Dec 2017: Fingolimod (Gilenya): updated advice about risk of cancers and serious infections
- MHRA Drug Safety Update Jan 2021: Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
- MHRA Drug Safety Update Jan 2021: Fingolimod (Gilenya): updated advice about the risks of serious liver injury and herpes meningoencephalitis
- MHRA Drug Safety Update May 2016: Pomalidomide (Imnovid): risk of hepatitis B reactivation
- MHRA Drug Safety Update Oct 2020: Niraparib (Zejula): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
- MHRA Drug Safety Update: Lenalidomide (Revlimid): update on risk of second primary malignancy
- MHRA Drug Sfety Update Sep 2019: Fingolimod (Gilenya): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
- MHRA Dug Safety Udate April 2016: Fingolimod (Gilenya): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections
- MHRA update on bradycardia and heart block
- MHRA: Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
- MHRA: Fingolimod (Gilenya▼): new contraindications in relation to cardiac risk
- MHRA: Fingolimod (Gilenya▼): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections
- MHRA: Fingolimod (Gilenya▼): updated advice about risk of cancers and serious infections
- MHRA: Fingolimod (Gilenya▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis
- MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA: Natalizumab (Tysabri▼): progressive multifocal leukoencephalopathy—updated advice to support early detection
- MHRA: Risk of thrombotic microangiopathy & nephrotic syndrome with interferon beta
MHRA: Safety update on risk of second primary malignancy- MHRA: Safety update on risk of thromboembolism
- NHS England national commissioning policy
- NHSE: National Cancer Drugs Fund list
- NICE New Medicine Evidence Summary 32: Relapsed and refractory multiple myeloma: pomalidomide
- NICE NG122 : Lung cancer: diagnosis and management
- NICE NG224: Melanoma: assessment and management
- NICE NG47: Haematological cancers: improving outcomes
- NICE NG52: Non-Hodgkin’s lymphoma: diagnosis and management
- NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin
- NICE TA 303: Teriflunomide for relapsing remitting MS
- NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma
- NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
- NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
- NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
- NICE TA127: Multiple sclerosis - natalizumab
- NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
- NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
- NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
- NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- NICE TA200:Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- NICE TA235: Osteosarcoma - mifamurtide: guidance
- NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
- NICE TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
- NICE TA281: Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)
- NICE TA302: Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)
- NICE TA32: Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
- NICE TA320: Dimethyl fumarate for multiple sclerosis
- NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
- NICE TA322: Lenalidomide for treating myelodysplastic syndromes
- NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
- NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
- NICE TA538: Dinutuximab beta for treating neuroblastoma
- NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
- NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
- NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
- NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
- NICE TA602: Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
- NICE TA603: Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)
- NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
- NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
- NICE TA656: Siponimod for treating secondary progressive multiple sclerosis
- NICE TA656: Siponimod for treating secondary progressive multiple sclerosis
- NICE TA662: Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)
- NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
- NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
- NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
- NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
- NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
- NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA767: Ponesimod for treating relapsing–remitting multiple sclerosis
- NICE TA767: Ponesimod for treating relapsing–remitting multiple sclerosis
- NICE TA774: Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)
- NICE TA784: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
- NICE TA794 : Diroximel fumarate for treating relapsing–remitting multiple sclerosis
- NICE TA794: Diroximel fumarate for treating relapsing–remitting multiple sclerosis
- NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
- NICE TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA828:Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA848 Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)
- NICE TA901:Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)
UKMI report on differences between bcg products